Agenus | AGEN - Ordinary Share Capital


Agenus reported $38.52M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 38.52M 3.2M Mar/2026
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 78.5M 11.93M Jun/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.64M Jun/2026
Jiangsu Hengrui CNY 6.64B 0 Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck EUR 434.78M 0 Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Northwest Biotherapeutics USD 1.61B 88.6M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 79.79M 1000 Jun/2026